esmolol has been researched along with metaproterenol in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Carlson, TA; Komadina, KH; Navratil, DL; Strollo, PJ | 1 |
| Klemm, H; Meinertz, T; Sturm, N; Ventura, R; Weiss, C; Willems, S | 1 |
| Heinke, W; Hund-Georgiadis, M; Olthoff, D; von Cramon, DY; Zysset, S | 1 |
1 review(s) available for esmolol and metaproterenol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for esmolol and metaproterenol
| Article | Year |
|---|---|
The effect of esmolol on cerebral blood flow, cerebral vasoreactivity, and cognitive performance: a functional magnetic resonance imaging study.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Blood Vessels; Cerebrovascular Circulation; Cognition; Female; Hemodynamics; Hemoglobins; Humans; Hyperventilation; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Metaproterenol; Muscle Tonus; Muscle, Smooth, Vascular; Neuropsychological Tests; Oxygen; Propanolamines; Psychomotor Performance; Reaction Time | 2005 |
5 other study(ies) available for esmolol and metaproterenol
| Article | Year |
|---|---|
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Electrophysiologic study of the effects of aminophylline and metaproterenol on canine myocardium.
Topics: Administration, Inhalation; Adrenergic beta-Antagonists; Aminophylline; Animals; Cardiac Pacing, Artificial; Dogs; Electrophysiology; Heart; Infusions, Intravenous; Metaproterenol; Propanolamines | 1992 |
Atrial premature beats in patients with focal atrial fibrillation: incidence at baseline and impact of provocative maneuvers.
Topics: Adenosine; Adrenergic Fibers; Atrial Fibrillation; Atrial Premature Complexes; Electrocardiography, Ambulatory; Electrophysiologic Techniques, Cardiac; Female; Humans; Male; Metaproterenol; Middle Aged; Propanolamines; Sodium Chloride; Vagus Nerve | 2002 |